Reliance Covid-19 Vaccine Is Arriving, Here’s Everything You Need To Know

Reliance is India’s one of the biggest conglomerates,which has been spreading its wings in all the directions.The empire which Mukesh Ambani built by the foundations of telecom services has now taken a new step by making its own Covid vaccine which is soon set to hit the Indian markets after it’s clinical trials.

 Phase I Trials To Begin

The Reliance group plans to leverage its existing businesses — pharmaceuticals, retail and technology for Covid-19 right from developing test kits, operating testing laboratories, to vaccine development, manufacturing and distribution.


Phase I testing marks the first time the vaccine is tested in a small group of adults, usually between 20 to 80 people, to evaluate its safety and measure the immune response it generates.After the successful completion of Phase I, the company can approach for PhaseII/III trials.Reliance had sought the regulator’s approval to conduct Phase 1 trial of its proposed two-dose vaccine and is expected to be conducted in a span of 58 days


RLS facility Navi Mumbai

The vaccine is being developed at the company’s Navi Mumbai facility, and is expected to be competitively priced considering the other vaccines and much  better efficacy claims the Reliance group.

Mechanism Of This Vaccine

This vaccine is a recombinant protein-based COVID-19 vaccine and similar to the Corbevax vaccine that was made by Biologica E in Hyderabad. The pharma company is also expected to apply for emergency use authorization that would make the vaccine available for temporary usage



Inside the RLS facility

Currently, there are six vaccines to have received emergency use authorization. Serum Institute’s Covishield, Bharat Biotech’s Covaxin, Russia’s Sputnik V, Moderna’s, Johnson & Johnson’s, and Cadila’s was approved last week.

Reliance is operating a high capacity Covid-19 RT-PCR and antibody testing laboratories across the country which consists of a high speed molecular transport medium for Covid-19 swab samples.Now inclusion of Vaccine development will surely boost the company’s future advancement in biotechnology and Indian pharmaceutical industries.